Sound Bioventures only invests in drug programs that a private syndicate can fund all the way to regulatory approval, takes board seats in nearly every company it backs, and has created an in-house role dedicated to spinning new companies out of overlooked academic or industry drug programs. It also stands out for publicly emphasizing decent, ethical venture capital, co-developing a framework to measure patient impact alongside financial returns, and dividing its portfolio roughly equally across Scandinavia, the U.S., and the rest of Europe.